Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Mahmoud F, Shields B, Makhoul I, Hutchins LF, Shalin SC, Tackett AJ.

Cancer Biol Ther. 2016 Jun 2;17(6):579-91. doi: 10.1080/15384047.2016.1167291. Epub 2016 Apr 22. Review.

2.

Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.

Dreger H, Ludwig A, Weller A, Stangl V, Baumann G, Meiners S, Stangl K.

Hypertension. 2012 Nov;60(5):1176-83. doi: 10.1161/HYPERTENSIONAHA.112.191098. Epub 2012 Sep 10.

PMID:
22966008
3.

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.

Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K.

Mol Cancer Ther. 2006 Dec;5(12):3096-104.

4.

Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.

Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, Choi YL, Mano H, Marquez VE, Hayashi T, Yanagihara K, Moriwaki Y, Miyazaki Y, Kamihira S, Yamada Y.

Haematologica. 2011 May;96(5):712-9. doi: 10.3324/haematol.2010.028605. Epub 2011 Jan 12.

5.

EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.

Tao J, Shi L, Huang L, Shi H, Chen H, Wang Y, Wang T.

J Cancer Res Clin Oncol. 2017 Nov;143(11):2211-2219. doi: 10.1007/s00432-017-2479-2. Epub 2017 Jul 26.

PMID:
28748258
6.

Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.

Gall Trošelj K, Novak Kujundzic R, Ugarkovic D.

Clin Epigenetics. 2016 May 27;8:55. doi: 10.1186/s13148-016-0226-1. eCollection 2016. Review.

7.

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33. doi: 10.1073/pnas.1202258109. Epub 2012 Mar 6.

8.

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.

Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.

9.

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.

Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, Madore J, Mann GJ, Hayward NK, McArthur GA, Filipp FV, Hersey P.

Oncotarget. 2015 Sep 29;6(29):27023-36. doi: 10.18632/oncotarget.4809.

10.

Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

Christofides A, Karantanos T, Bardhan K, Boussiotis VA.

Oncotarget. 2016 Dec 20;7(51):85624-85640. doi: 10.18632/oncotarget.12928. Review.

11.

The potential roles of EZH2 in regenerative medicine.

Chou RH, Chiu L, Yu YL, Shyu WC.

Cell Transplant. 2015;24(3):313-7. doi: 10.3727/096368915X686823. Epub 2015 Feb 2. Review.

PMID:
25647295
12.

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Jones BA, Varambally S, Arend RC.

Mol Cancer Ther. 2018 Mar;17(3):591-602. doi: 10.1158/1535-7163.MCT-17-0437. Review.

13.

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.

Agarwal P, Alzrigat M, Párraga AA, Enroth S, Singh U, Ungerstedt J, Österborg A, Brown PJ, Ma A, Jin J, Nilsson K, Öberg F, Kalushkova A, Jernberg-Wiklund H.

Oncotarget. 2016 Feb 9;7(6):6809-23. doi: 10.18632/oncotarget.6843.

14.

EZH2 as a mediator of treatment resistance in melanoma.

Tiffen JC, Gallagher SJ, Tseng HY, Filipp FV, Fazekas de St. Groth B, Hersey P.

Pigment Cell Melanoma Res. 2016 Sep;29(5):500-7. doi: 10.1111/pcmr.12481. Epub 2016 May 25. Review.

15.

EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.

Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X, Yuan GC, Orkin SH.

Mol Cell. 2008 Nov 21;32(4):491-502. doi: 10.1016/j.molcel.2008.10.016.

16.

Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.

Jie B, Weilong C, Ming C, Fei X, Xinghua L, Junhua C, Guobin W, Kaixiong T, Xiaoming S.

Int J Biochem Cell Biol. 2015 Aug;65:104-12. doi: 10.1016/j.biocel.2015.05.011. Epub 2015 May 22.

PMID:
26004298
17.
18.

Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.

Song X, Zhang L, Gao T, Ye T, Zhu Y, Lei Q, Feng Q, He B, Deng H, Yu L.

Biomed Pharmacother. 2016 Jul;81:288-294. doi: 10.1016/j.biopha.2016.04.019. Epub 2016 Apr 25.

PMID:
27261606
19.

EZH2 methyltransferase and H3K27 methylation in breast cancer.

Yoo KH, Hennighausen L.

Int J Biol Sci. 2012;8(1):59-65. Epub 2011 Nov 18. Review.

20.

Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency.

Nguyen K, Das B, Dobrowolski C, Karn J.

MBio. 2017 Feb 28;8(1). pii: e00133-17. doi: 10.1128/mBio.00133-17.

Supplemental Content

Support Center